NYSEAMERICAN:ATNM - Actinium Pharmaceuticals, Inc.
$0.25
 $0.01
+4.69%
12:30PM EDT
2019-07-22
Actinium Pharmaceuticals, Inc. (Actinium), incorporated on March 20, 2013, is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy (APIT) platform and other related technologies. The Company's products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131). Actimab-A is in human clinical trials stage for acute myeloid leukemia (AML) and Iomab-B in clinical trial stage for use in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications. Actinium's products under development are monoclonal antibodies labeled with radioisotopes. It has four product candidates in clinical trials: Actimab-A (HuM195-Ac-225), Iomab-B (BC8-I-131), BC8-Y-90 and BC8-SA. The Company is pursuing development of Actimab-A and Iomab-B, while BC8-Y-90 and BC8-SA are in physician sponsored clinical phase I trials at the Fred Hutchinson Cancer Research Center (FHCRC).Actinium, together with its subsidiary, MedActinium, Inc. (MAI), (collectively known as Actinium) has initiated collaborative efforts with large institutions to establish the alpha particle immunotherapy and has supported one Phase I/II clinical trial and one Phase I clinical trial at Memorial Sloan-Kettering Cancer Center (MSKCC) under an MSKCC Physician Investigational New Drug Application (IND) Application. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  ATNM     avg for
industry  
  avg for
sector  
42 stocks weight:  2. 20   217. 37   399. 45  
42 stocks rank:  4. 42 K 1. 27 K 716. 99  
# analyst opinions:  3. 00   13. 21   13. 71  
mean recommendation:  2. 00   2. 10   2. 04  

quick ratio:  1. 70   5. 49   1. 88  
current ratio:  1. 75   5. 87   2. 36  

target price low:  0. 15   83. 44   114. 90  
target price avg:  0. 34   106. 20   137. 90  
target price high:  0. 47   132. 30   158. 97  
1-yr high:  0. 82   111. 86   142. 57  
last close:  0. 24   86. 79   125. 44  
50-day avg:  0. 26   86. 68   122. 63  
200-day avg:  0. 46   89. 22   121. 38  
1-yr low:  0. 23   69. 78   100. 51  
volume:  342. 21 K 2. 62 M 3. 43 M
50-day avg volume:  1. 18 M 3. 20 M 4. 16 M
200-day avg volume:  1. 06 M 2. 99 M 4. 75 M

1-day return:  1. 49 % -1. 30 % -0. 99 %
this week return:  2. 89 % 0. 45 % -0. 20 %
12-wk return:  -18. 53 % 0. 94 % 4. 84 %
52-wk return:  -69. 78 % -1. 30 % 10. 55 %

enterprise value (EV):  28. 97 M 45. 10 B 122. 38 B
market cap:  38. 68 M 38. 96 B 108. 40 B
EBITDA:  -23. 03 M 4. 20 B 8. 19 B
enterprise multiple (EV/EBITDA):  -1. 26   5. 38   11. 93  
total debt:  1. 57 M 10. 90 B 17. 48 B
debt/equity:  29. 47   57. 18   120. 05  
net income (common):  -23. 00 M 2. 07 B 4. 05 B

shares outstanding:  162. 03 M 538. 09 M 1. 24 B
shares:  147. 46 M 548. 00 M 1. 22 B
shares short:  4. 06 M 10. 98 M 11. 87 M
shares short prior month:  2. 46 M 9. 32 M 12. 05 M
short ratio:  2. 77   5. 60   3. 34  
short % of float:  3. 47 % 6. 48 % 2. 64 %
total cash/share:  0. 06   10. 98   9. 19  
total cash:  9. 92 M 5. 93 B 6. 10 B
free cash flow:  -13. 44 M 2. 92 B 4. 55 B
operating cash flow:  -20. 60 M 3. 80 B 5. 78 B

book value:  0. 04   13. 35   27. 45  
price/book:  5. 30   4. 60   8. 78  
operating margins:  0. 00 % -308. 40 % -28. 55 %
EBITDA margins:  0. 00 % 13. 17 % 23. 38 %
profit margins:  0. 00 % 10. 44 % 14. 18 %
gross margins:  0. 00 % 35. 80 % 55. 40 %

1-yr max volatility:  31. 29 % --- ---
1-yr mean volatility:  3. 23 % 1. 66 % 1. 03 %

1-yr EPS:  -0. 20   2. 10   4. 23  
forward EPS:  -0. 09   3. 45   7. 10  
P/E:  -1. 18   1. 90   32. 10  
forward P/E:  -2. 61   6. 46   15. 47  
PE/G:  0. 03   0. 70   -0. 54  
growth:  -43. 63 % 265. 63 % 79. 11 %
earnings high:  -0. 04   0. 89   1. 68  
earnings avg:  -0. 04   0. 70   1. 57  
earnings low:  -0. 05   0. 46   1. 46  
revenue high:  -0. 00   2. 57 B 11. 07 B
revenue avg:  -0. 00   2. 51 B 10. 91 B
revenue low:  -0. 00   2. 45 B 10. 73 B
return on assets:  -71. 74 % -2. 34 % 5. 28 %
return on equity:  -169. 81 % -90. 08 % 133. 53 %

beta (1yr vs S&P500):  1. 01   1. 27   0. 91  
sharpe (1yr):  -1. 15   0. 16   0. 77  

held % insiders:  1. 30 % 6. 06 % 3. 29 %
held % institutions:  12. 47 % 78. 22 % 69. 37 %

Research more with google or yahoo!
the data below are updated and re-published at 8pm EDT after each trading day

2019-07-21 : ATNM
.    100.634 =       100.634 :: --> INITIAL WEIGHT <--
.    - 0.203 =       100.431 :: earnings per-share addition
.                               --> FUNDAMENTALS <--
.    x 1.982 =       199.052 :: P/E factor
.    x 2.209 =       439.697 :: PE/G factor
.    x 1.446 =       635.948 :: beta factor
.    x 0.909 =       578.144 :: sharpe factor
.    x 2.299 =      1329.004 :: current ratio factor
.    x 1.483 =      1971.016 :: quick ratio factor
.    x 1.167 =      2299.434 :: short ratio factor
.    x 1.065 =      2449.549 :: price-to-book factor
.    x 1.231 =      3015.387 :: debt-to-equity factor
.                               --> PERFORMANCE <--
.    x 2.121 =      6395.013 :: sector+industry 1-year gains factor
.    x 1.009 =      6455.305 :: industry 12-weeks return factor
.    x 1.308 =       8442.82 :: industry 2-weeks return factor
.    x 0.994 =      8394.491 :: "drift" penalty 1 days ago
.    x 0.979 =      8214.071 :: "drift" penalty 2 days ago
.    x 0.999 =      8206.469 :: "drift" penalty 4 days ago
.    / 2.043 =      4016.047 :: overall "drift" factor
.    x 0.883 =      3544.558 :: largest single-day jump factor
.    x 0.059 =       209.226 :: low price factor
.    x 0.087 =        18.284 :: notable returns + performance factor
.                               --> PROJECTIONS <--
.    x 0.008 =         0.148 :: forward EPS factor
.     x 0.64 =         0.095 :: forward P/E factor
.    x 1.185 =         0.112 :: industry recommendation factor
.    x 2.122 =         0.238 :: company recommendation factor
.    x 1.003 =         0.239 :: factor historical industry gain for week 29
.    x 0.907 =         0.217 :: target low factor
.    x 1.219 =         0.264 :: target mean factor
.    x 1.042 =         0.275 :: target high factor
.    x 9.675 =         2.661 :: spline projection factor
.                               --> FINAL ADJUSTMENTS <--
.  quad root =         1.277 :: reduced for readability
.    + 0.927 =         2.204 :: add/subtract for investor sentiment
.                               --> FINAL WEIGHT <--
.                      2.204 :: FINAL WEIGHT for NYSEAMERICAN:ATNM


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org